Michelle McMurry-Heath (BIO via YouTube)
October 9, 2022 11:53 PM EDTUpdated 06:10 AM
People
FDA+

BIO chief Mc­Mur­ry-Heath on leave as storm clouds gath­er over group’s di­rec­tion, leg­isla­tive set­back

John Carroll

Editor & Founder

Af­ter a short, rocky two-year tenure high­light­ed by an event-killing pan­dem­ic, cut­backs and new pric­ing leg­is­la­tion wide­ly viewed in biotech as a calami­ty, BIO CEO …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times